1

Unitaid

Strategy and Investment Portfolio

October 2018

2

Agenda

2

Strategy 2017 - 2021

Investment Portfolio

2016-06-30-UNITAID strategy -IAS Durban-v7-UPDATED.pptx 3

Maximize the effectiveness

of the global health response

better health products

catalyzing equitable access

Our mission

by to

4

Upstream

Systems

Innovation & Availability

Devices

Supply & Delivery

Medicines

Quality

Demand & Adoption

Affordability

Unitaid connects the upstream to the downstream

HIV/AIDS Tuberculosis Malaria

Downstream

PDPs BMGF Industry Academia Others Grand

Challenges

…

4

5

Global Goals

Challenges

Opportunities

Areas for interventions

Calls for proposals

Projects

Disease narratives

Disease Narrative – Malaria

Disease Narrative – Tuberculosis

Disease Narrative – HIV

Disease Narrative – Hepatitis C

in the context of co-infection with

HIV

Areas for intervention

HIV E.g. Scale-up of PrEP

TB E.g. Latent TB

Malaria E.g. IPTp

HCV E.g. Simple, rapid diagnosis of HCV

Projects

Unitaid translates global goals into concrete projects

5

6

Challenges are prioritized with a systematic analysis

6

UNITAID's landscapes

Global strategies

Ongoing partner consultation

Civil society Technical partners

Funding partners

Governments

Private sector Implementers

Partners' strategies & reports

Technology availability

Health product access 1

2

3

Critical gap

4

Public health impact

Challenge A Challenge B Challenge C Challenge D

Challenge A Challenge C

Unitaid plays a role at 3 critical moments

7

Objectives Innovation Scalability Access

Moment 2 Product is adopted

Moment 3 Product is scaled-up

Moment 1 Product is available

Pro

du

ct c

ove

rage

Maximize the effectiveness of the

global health response...

... by catalyzing equitable access...

... to better health products

The cascade of care

Test

Prevent

Treat Monitor

9

Current portfolio Grants in development New AFI

Advanced HIV disease

Reduce AIDS-related mortality to

500,000 deaths by 2020

Children Adults

New grants- PrEP

Test

Prevent

Treat Monitor

Viral Load ~ US$173m

STAR Self-

testing ~

US$ 80m EID

~US$

100m

Cro

ss

-cu

tting

ATLAS -

Self testing

WH

O E

na

ble

r, WH

O P

Q,

MP

P, IT

PC

HIV and co-infection portfolio

ARV portfolio

~US$ 118m

PrEP~ US$26m

HCV diagnosis HCV treatment

Unitaid’s investments in TB

Test

Prevent

Treat

Scale-up better TB treatment for children

Enable preventive TB treatment in high-risk

groups

Better, shorter treatment for MDR-TB

Monitor (adherence)

MDR TB

Grants in development/calls

Unitaid’s investments in TB

Test

Prevent

Treat

TB-SPEED (Univ Bordeaux)

IMPAACT4TB (Aurum)

endTB (Partners in Health)

Adherence (monitor)

CAP TB (EGPAF)

WHO Enabler Other CC: MPP & PQ

Unitaid’s investments in Malaria

Current portfolio Grants in development/calls New AFI

Refer

Treat

Treat

Cro

ss-cuttin

g

MM

V su

pp

ly, WH

O e

nab

ler, W

HO

PQ

RTS,s (WHO)

Test Prevent

Vector control

Catalytic LLIN (IVCC)

TIPTOP

(JHPIEGO)

NGenIRS (IVCC)

Fever Dx

New grants

RAS (CHAI) Signs of

Severe disease

Thank you